Association of American Physicians and Surgeons: Warns of Surprise Attack on Patients’ Choices

December 14, 2020

Association of American Physicians and Surgeons (AAPS) warns that the so-called No Surprises Act is really an insurance company protection bill. “Poised to be rushed through in the final days of the lame-duck Congress, [it] is a surprise attack on patients’ access to independent physicians.”

Association of American Physicians and Surgeons alert states: “Proponents claim the bill (which does not yet have a bill number) is needed to protect patients from so-called surprise bills. Unfortunately, this problem caused in large part by past policy failures like [the Affordable Care Act] is not going to be fixed by 357 new pages of federal regulation. In fact the legislation is full of bad surprises that will result in decreased patient choice and the closure of more independent medical practices.”

Among the bad surprises, the Association of American Physicians and Surgeons Alert lists the following:

  • “It adds red tape to both patients seeking care out-of-network and independent physicians providing that care.”
  • “Insurers and government bureaucrats will exert even greater control over patient care, especially care that is needed in emergency life or death situations.”
  • “Section 115 creates a federal claims database inimical to patient privacy.”
  • “Section 117 may require any independent physician to submit an insurance claim for patients who have commercial insurance…. This provision has unclear and potentially harmful implications for the ability of patients and physicians to enter into third-party-free relationships.”

Association of American Physicians and Surgeons concludes that the bill “greatly increases the power of government over American medicine” and urges members to tell Congress that the “[‘No Surprises Act’] should not be added to bills being rushed through before Christmas and that it will reduce patient access to independent physicians who work for the patient and not for the benefit of the insurance plan’s bottom line.”

AAPS has represented physicians of all specialties in all states since 1943. The AAPS motto is omnia pro aegroto, meaning everything for the patient.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version